| 초록 |
Herein, a triple padlock nanocarrier prepared by a modified chondroitin sulfate A (TCSA) is designed to develop an oral dosage form of recombinant human teriparatide (rhPTH). We developed a TCA-conjugated CSA (TCSA) nanocarrier as a triple padlock system for oral delivery of recombinant human teriparatide [rhPTH (1–34)] against osteoporosis. In this research, we showed that the TCSA-triple padlock system facilitates protection of encapsulated rhPTH (1–34) from gastric or enzymatic degradation in the GIT and ASBAT- or OST α/β-mediated reabsorption of the TCSA/rhPTH nanocomplex, along with the prolonged t1/2, stimulates new bone formation, and reduces osteoporotic fracture by delivering the rhPTH to the type-1 PTH receptor (PTHr-1) through the intestinal portal system. This triple padlock oral delivery platform overcame the current barriers associated with teriparatide administration and exhibited a promising therapeutic effect against osteoporosis. |
